Home › Compare › YMDAF vs ABBV
YMDAF yields 3.70% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, YMDAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YMDAF + ABBV for your $10,000?
Yamada Holdings Co., Ltd., together with its subsidiaries, operates in the consumer electronics retailing activities. Its Consumer Electronics segment operates a network of consumer electronics stores that sell home appliances, home interiors, and living and furniture products, as well as engages in the specialty retailing of private label apparel products. The company's Housing segment provides smart and custom-built homes, as well as engages in home building, rebuilding, and sale, and renovation activities. Its Finance segment develops a range of financial products in the new builds, renovations, payment services, insurance products, and life planning. The company's Environmental segment is involved in the product reuse and recycling, waste reduction and disposal, and recycled materials usage activities. Its Other segment engages in the trading businesses in travel industry, and delivery and installation of electrical appliances. The company was formerly known as Yamada Denki Co., Ltd. and changed its name to Yamada Holdings Co., Ltd. in October 2020. Yamada Holdings Co., Ltd. was founded in 1973 and is headquartered in Takasaki, Japan.
Full YMDAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.